Skip to content

ONC · BeOne Medicines Ltd.

32 filings

10-Q

ONC 10-Q Quarterly Reports

BeOne Medicines Ltd. - 32 quarterly reports

Filing record · 2016–202610-K1310-Q328-K284

2026-Q2
BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2026
BeOne Medicines Ltd. reported a strong second quarter for 2026, with total revenues increasing by 29.6% year-over-year to $1.71 billion. This growth was primarily driven by a 29.0% increase in product revenue, largely attributed to robust global sales of BRUKINSA®, which saw a 31.4% year-over-year increase. The company also experienced significant growth in other revenue streams, up 91.1%, indicating positive momentum across its portfolio. Despite increased revenue, net income saw a substantial increase of 151.3% to $237 million, reflecting improved operating leverage and effective cost management, as demonstrated by the increase in gross margin to 89.6%. Research and development expenses increased by 16.6%, supporting pipeline advancement, while selling, general, and administrative expenses grew by 10.3%, primarily due to global commercial expansion. The company generated strong operating cash flow, a key indicator of financial health and sustainability.
Aug 5, 2026
2026-Q1
BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2026
BeOne Medicines Ltd. reported a significant increase in revenue for the first quarter of 2026, reaching $1.51 billion, a 35.5% rise compared to the prior year period. This growth was primarily driven by strong sales of BRUKINSA®, which saw a 38.3% increase, and improved performance from TEVIMBRA® and in-licensed Amgen products. The company achieved positive net income of $227.4 million, a substantial improvement from the $1.3 million reported in the first quarter of 2025, translating to diluted EPS of $0.15. Operating expenses also increased, with R&D up 12.3% and SG&A up 20.9%, reflecting continued investment in pipeline development and commercial expansion. Despite these investments, income from operations surged to $250 million, a significant jump from $11.1 million in the prior year. The company ended the quarter with a strong cash position of $4.85 billion, and free cash flow turned positive at $160.5 million, indicating improving operational efficiency and financial health.
May 6, 2026
2025-Q3
BeOne Medicines Ltd. Quarterly Report for Q3 Ended Sep 30, 2025
BeOne Medicines Ltd. (ONC) reported a strong third quarter of 2025, with total revenues reaching $1.41 billion, a significant 41% increase year-over-year. This growth was primarily driven by robust performance in product revenue, which rose 40.4% to $1.395 billion, led by a remarkable 50.8% surge in BRUKINSA® sales, now exceeding $1 billion globally for the quarter. The company also demonstrated improved profitability, swinging from a net loss in the prior year period to a net income of $124.8 million. This financial turnaround, coupled with an increase in R&D investment and SG&A expenses, reflects BeOne Medicines' strategic focus on expanding its commercial reach and advancing its promising oncology pipeline.
Nov 6, 2025
2025-Q2
BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2025
BeOne Medicines Ltd. reported a strong second quarter for 2025, demonstrating significant year-over-year revenue growth driven by its key oncology products. Total revenues increased by 41.6% to $1.32 billion, primarily fueled by a 41.4% rise in product revenue, with BRUKINSA® sales alone surging 49.0% to $950 million globally. This robust top-line growth, coupled with improving gross margins and disciplined operating expense management, allowed the company to achieve a positive GAAP net income of $94.3 million, a substantial improvement from the net loss in the prior year's comparable period. The company also highlighted significant progress in its pipeline, anticipating over 20 R&D milestones in the next 18 months. Operationally, BeOne Medicines is effectively scaling its commercial capabilities, particularly in the U.S. and Europe, which are key drivers for BRUKINSA's continued market leadership. The company's strategic focus on expanding its oncology franchise is evident in its R&D day announcements and positive clinical development updates. While R&D and SG&A expenses increased to support this growth, they were managed effectively relative to revenue growth, leading to improved operating leverage and a shift from an operating loss to an operating profit. The company also successfully completed its redomiciliation to Switzerland and updated its name, marking a significant corporate milestone.
Aug 6, 2025
2025-Q1
BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2025
Beigene, Ltd. (ONC) demonstrated a significant financial turnaround in the first quarter of 2025, reporting GAAP net income of $1.27 million compared to a net loss of $251.15 million in the prior year period. This improvement was driven by a substantial 48.6% increase in total revenues to $1.12 billion, primarily fueled by a 48.4% surge in product revenue to $1.11 billion. The company's flagship product, BRUKINSA®, saw a remarkable 62.1% increase in global sales, reaching $791.7 million, and now leads in new patient starts and market share in the U.S. for BTKi. Despite the revenue growth and return to profitability, operating expenses, particularly research and development, saw a modest increase of 4.6% to $481.9 million, and selling, general, and administrative expenses increased by 7.5% to $459.3 million, reflecting continued investment in pipeline advancement and commercial expansion. The company ended the quarter with a strong liquidity position, holding $2.53 billion in cash, cash equivalents, and restricted cash, while successfully reducing its total debt. The strategic focus on expanding its oncology pipeline, coupled with positive sales momentum for its key products, positions Beigene for continued growth.
May 7, 2025
2024-Q3
BeOne Medicines Ltd. Quarterly Report for Q3 Ended Sep 30, 2024
BeiGene, Ltd. (ONC) reported a significant increase in total revenues for the third quarter of 2024, reaching $1,001.6 million, up 28.2% year-over-year, driven primarily by strong product revenue growth. Product revenue surged by 66.9% to $993.4 million, largely fueled by the exceptional performance of BRUKINSA, which saw a 93.0% increase in global sales, particularly in the U.S. and Europe. Despite a substantial increase in operating expenses, the company managed to reduce its net loss. While collaboration revenue decreased significantly due to prior-year terminations, the robust growth in product sales underscores the increasing market acceptance and commercial success of BeiGene's key oncology medicines. The company continues to invest heavily in research and development, with R&D expenses increasing by 9.5% to $496.2 million, reflecting its commitment to pipeline advancement. Selling, general, and administrative expenses also saw an increase of 24.5% to $455.2 million, supporting the global commercial expansion. BeiGene ended the quarter with a healthy cash position of $2,701.9 million, providing ample liquidity for ongoing operations and future growth initiatives. Investors should note the ongoing legal proceedings related to patent infringement and trade secrets, which could present future risks.
Nov 12, 2024
2024-Q2
BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2024
Beigene, Ltd. (ONC) reported a significant increase in total revenues for the second quarter of 2024, reaching $929.2 million, a 56% rise compared to the same period last year. This growth was primarily driven by a substantial 107% increase in BRUKINSA sales, totaling $637.4 million globally, with particularly strong performance in the U.S. and Europe. Despite the revenue growth, the company reported a GAAP net loss of $120.4 million for the quarter. The company also highlighted its strategic advancements, including the opening of its new U.S. facility in Hopewell, New Jersey, and progress in its pivotal programs for sonrotoclax and BGB-16673. While the company's operating loss narrowed significantly, it continues to invest heavily in research and development and selling, general, and administrative expenses to support its product pipeline and commercialization efforts. Investors should note the significant decline in collaboration revenue due to the termination of prior agreements, which is more than offset by the robust growth in product revenue. The company's cash position remains strong at $2.6 billion, though it is managing a substantial amount of debt, with over $851 million due within the next 12 months. Beigene appears to be on a positive trajectory with its key product, BRUKINSA, gaining market share and driving substantial revenue growth, but continued investment in R&D and commercial expansion will be crucial for future profitability.
Aug 7, 2024
2024-Q1
BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2024
BeiGene, Ltd. reported a significant increase in total revenues to $751.7 million for the first quarter of 2024, up 67.9% from the prior year, driven primarily by an 82.0% surge in product revenue to $746.9 million. This growth was predominantly fueled by strong performance in BRUKINSA, which saw a 131.1% year-over-year increase in net product revenue to $488.5 million, with notable expansion in the U.S. and Europe. The company continues to invest heavily in research and development, with R&D expenses increasing by 12.7% to $460.6 million, supporting its broad pipeline. Despite increased operating expenses, the company highlights improved operating leverage and progress towards sustainable profitability. However, BeiGene reported a net loss of $251.2 million for the quarter, although this represents an improvement compared to the $348.4 million net loss in the same period last year. Financially, BeiGene maintains a strong liquidity position with $2.8 billion in cash, cash equivalents, and restricted cash as of March 31, 2024. The company's total debt stands at $1.03 billion, with a significant portion maturing within the next 12 months. While the company is actively managing its growth and pipeline development, investors should monitor its continued progress in commercializing its approved medicines and advancing its pipeline candidates, alongside its efforts to manage increasing operational costs.
May 8, 2024
2023-Q3
BeOne Medicines Ltd. Quarterly Report for Q3 Ended Sep 30, 2023
BeiGene, Ltd. (ONC) reported a strong third quarter of 2023, with total revenues soaring to $781.3 million, a significant increase of 101.6% year-over-year. This growth was primarily driven by a substantial 70.3% increase in product revenue, reaching $595.3 million, largely attributed to the continued strong performance of BRUKINSA, which saw a 130.0% rise in global sales. The company also benefited from increased collaboration revenue, notably from the termination of agreements with Novartis, which recognized remaining deferred revenue. Despite a reported net loss of $514.2 million for the first nine months of the year, the quarter itself showed a net income of $215.4 million, indicating a positive operational trend. The company ended the quarter with a robust cash position of $3.1 billion, positioning it well to fund its operations for at least the next 12 months. Key strategic developments include regaining global rights to TEVIMBRA, which strengthens the company's oncology portfolio, and receiving positive opinions for BRUKINSA's reimbursement in the UK and for a new indication in the EU. Management highlighted plans to improve operating leverage and moderate expense growth. The company's continued investment in R&D and commercial capabilities, including the ongoing construction of its Hopewell facility in New Jersey, underscores its commitment to expanding its global reach and product pipeline.
Nov 9, 2023
2023-Q2
BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2023
BeiGene, Ltd. (ONC) reported its second quarter 2023 financial results, showcasing significant revenue growth driven by strong performance in its key products, BRUKINSA and tislelizumab. Total revenues surged by 74.3% year-over-year, reaching $595.3 million, primarily due to an 81.8% increase in product revenue to $553.7 million. This growth was fueled by substantial increases in BRUKINSA sales, particularly in the U.S. and Europe, and continued strong sales of tislelizumab in China. Collaboration revenue also saw a modest increase of 12.0%. Despite the top-line growth, the company's operating expenses increased by 17.0%, leading to a continued net loss of $381.1 million for the quarter. However, the net loss narrowed by 32.6% compared to the same period last year, reflecting the significant revenue growth. The company ended the quarter with a strong cash position of $3.4 billion, providing a substantial runway for continued investment in its pipeline and operations.
Aug 2, 2023
2023-Q1
BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2023
BeiGene, Ltd. (ONC) reported a solid increase in total revenues for the first quarter of 2023, driven primarily by a substantial 56.9% year-over-year growth in net product revenue. This growth was largely fueled by strong performance in BRUKINSA sales, which more than doubled, and a notable 31.0% increase in tislelizumab sales, both benefiting from expanded market access and reimbursement in key markets like China and the U.S. While revenues are increasing, the company continues to invest heavily in research and development, leading to a net loss of $348.4 million for the quarter. Despite the ongoing net loss, BeiGene ended the quarter with a strong cash position of $3.54 billion, providing a significant runway for its extensive clinical development programs and global expansion efforts. The company's liquidity appears sufficient for the next twelve months, but future funding needs for its ambitious pipeline remain a consideration.
May 4, 2023
2022-Q3
BeOne Medicines Ltd. Quarterly Report for Q3 Ended Sep 30, 2022
Beigene, Ltd. (ONC) reported its third quarter 2022 financial results, showcasing significant year-over-year growth in product revenue driven by strong performance of its key oncology drugs, BRUKINSA® and tislelizumab. Total revenues saw a substantial increase primarily due to a surge in product sales, more than offsetting a decline in collaboration revenue which was impacted by the prior year's recognition of an upfront payment from Novartis. While operating expenses, particularly in research and development and selling, general, and administrative functions, also increased to support global expansion and pipeline development, the company demonstrated improved gross margins. Beigene continues to manage its cash reserves effectively, reporting a solid cash balance despite ongoing investments in its growth initiatives. The company also disclosed revisions to prior period financial statements to correct an error related to the valuation of net deferred tax assets.
Nov 9, 2022
2022-Q2
BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2022
BeiGene, Ltd. (ONC) reported significant revenue growth driven by strong sales of its key products, particularly BRUKINSA® and tislelizumab, which saw increases of 119.7% and 40.1% respectively in the second quarter of 2022 compared to the prior year period. Despite this top-line growth, the company continued to experience substantial net losses, amounting to $571.4 million for the quarter and $1.0 billion for the first six months of 2022, reflecting ongoing heavy investment in research and development and selling, general, and administrative expenses. The company ended the period with a strong cash position of $4.5 billion, providing what management believes is sufficient liquidity for at least the next 12 months, though future funding needs for ongoing development and commercialization efforts are anticipated. The significant increase in revenue is a positive indicator of market adoption for BeiGene's core therapies. However, the continued operating losses highlight the capital-intensive nature of drug development and commercialization in the biotechnology sector. Investors should monitor the company's progress in advancing its pipeline, managing its substantial R&D spend, and its ability to eventually achieve profitability while navigating a complex global regulatory and market landscape.
Aug 8, 2022
2022-Q1
BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2022
BeiGene, Ltd. (ONC) reported its first-quarter 2022 financial results, showcasing a significant surge in product revenue, which more than doubled compared to the prior year period, primarily driven by strong sales of BRUKINSA® and tislelizumab in key markets like the U.S. and China. This growth was further bolstered by the inclusion of new products like BLINCYTO®, KYPROLIS®, and POBEVCY® in its distribution portfolio. However, total revenue experienced a substantial decline year-over-year, largely due to the absence of a significant upfront collaboration payment from Novartis that was recognized in the prior year quarter. Despite the revenue shift, the company's product sales demonstrate robust underlying demand, supported by expanding reimbursement coverage. Operationally, BeiGene reported a net loss for the quarter, a reversal from the net income in the prior year, primarily due to a substantial increase in research and development (R&D) and selling, general, and administrative (SG&A) expenses. These increased expenses reflect the company's strategic investments in expanding its global development organization, clinical pipeline, commercial capabilities, and broader R&D activities. The company maintained a strong liquidity position with significant cash and short-term investments, providing a runway for its ongoing operations and development programs.
May 9, 2022
2021-Q3
BeOne Medicines Ltd. Quarterly Report for Q3 Ended Sep 30, 2021
BeiGene, Ltd. (BeiGene) reported robust revenue growth in the third quarter of 2021, driven by strong performance of its internally developed products, BRUKINSA® and tislelizumab, as well as in-licensed products. Total revenue surged by 126.7% year-over-year to $206.4 million. Product revenue, in particular, more than doubled to $192.5 million, fueled by significant increases in BRUKINSA® sales in the U.S. and China, and continued strong sales of tislelizumab in China. The company also saw positive contributions from newly launched products like pamiparib and Amgen's XGEVA® and BLINCYTO® in China. Despite the impressive revenue growth, BeiGene reported a net loss of $413.9 million for the quarter. This was primarily driven by substantial investments in research and development, which increased slightly year-over-year to $351.9 million, and a significant rise in selling, general, and administrative expenses, up 67.4% to $269.2 million, reflecting the expansion of its global commercial and R&D organizations. The company ended the quarter with a strong cash position of approximately $1.39 billion in cash, cash equivalents, and restricted cash, supported by a substantial $2.5 billion in short-term investments.
Nov 4, 2021
2021-Q2
BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2021
BeiGene, Ltd. (ONC) reported strong revenue growth in its Q2 2021 filing, with total revenues reaching $150.0 million, a significant increase from $65.6 million in the prior year period. This growth was driven by substantial increases in product revenue, particularly from its internally developed medicines BRUKINSA® and tislelizumab, as well as the addition of collaboration revenue from the Novartis agreement. The company's R&D expenses also saw an increase, reflecting continued investment in its pipeline. Despite a net loss of $480.3 million for the quarter, the company maintains a robust cash position, ending the period with over $1.7 billion in cash, cash equivalents, and restricted cash, bolstered by recent financing activities and upfront payments from collaborations. Key developments during the quarter included positive results from the Phase 3 SEQUOIA trial for BRUKINSA® and multiple regulatory updates for its product candidates.
Aug 5, 2021
2021-Q1
BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2021
BeiGene, Ltd. (ONC) reported a significant increase in total revenues for the first quarter of 2021, reaching $605.9 million compared to $52.1 million in the prior year period. This growth was primarily driven by a substantial $499.8 million in collaboration revenue, largely attributed to the upfront payment from the Novartis agreement for tislelizumab, and a notable increase in product revenue, which grew by 103.8% to $106.1 million. The company's product revenue growth was fueled by strong performance of its internally developed drugs, BRUKINSA® and tislelizumab, along with the inclusion of XGEVA® in sales distribution. Despite the revenue surge, operating expenses also increased, with R&D expenses up 5.4% to $320.7 million and SG&A expenses up 70.1% to $182.1 million, reflecting ongoing investment in growth. Financially, the company reported a net income of $66.5 million for the quarter, a significant turnaround from the net loss of $364.9 million in the same period last year. This positive net income was substantially bolstered by the collaboration revenue. The company's liquidity remains strong, with cash, cash equivalents, and short-term investments totaling approximately $4.8 billion as of March 31, 2021, providing ample runway for its operations. Investors should note the substantial increase in SG&A expenses, which will be crucial to monitor as the company continues its global commercialization efforts.
May 6, 2021
2020-Q3
BeOne Medicines Ltd. Quarterly Report for Q3 Ended Sep 30, 2020
Beigene, Ltd.'s (ONC) third quarter 2020 filing shows a significant increase in total assets, largely driven by substantial growth in cash and cash equivalents and short-term investments. Revenue grew by 81.6% year-over-year for the quarter, primarily due to strong performance of internally developed products like tislelizumab and BRUKINSA®, along with initial sales of XGEVA®. However, the company continues to report substantial net losses, with research and development (R&D) and selling, general, and administrative (SG&A) expenses increasing significantly year-over-year. The company successfully raised substantial capital through a registered direct offering in July 2020, bolstering its liquidity position to over $4.7 billion in cash, cash equivalents, and short-term investments as of September 30, 2020. The company's strategic collaborations, particularly with Amgen, are progressing, with significant upfront payments and a co-development funding commitment contributing to the financial landscape. However, challenges persist, including the suspension of ABRAXANE® sales in China and potential impacts from the COVID-19 pandemic on clinical trial recruitment and commercial operations. Despite the ongoing net losses, the substantial cash reserves provide a runway for continued investment in R&D and commercial expansion.
Nov 5, 2020
2020-Q2
BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2020
BeiGene, Ltd. (ONC) reported its financial results for the second quarter and the first six months of 2020. The company experienced a significant year-over-year decline in total revenues, primarily due to the absence of collaboration revenue compared to the previous year's period, which included a substantial termination fee from a BMS collaboration. However, net product revenues showed growth, driven by increased sales of internally developed products like tislelizumab and BRUKINSA®, partially offset by a decline in ABRAXANE® sales due to regulatory suspension in China. Research and development expenses saw a notable increase, reflecting continued investment in clinical drug candidates and co-development obligations with Amgen. Selling, general, and administrative expenses also rose significantly, driven by increased headcount and expansion of commercial operations. Despite reporting a substantial net loss, the company's cash position remained strong, bolstered by a significant equity financing round in July 2020, providing ample liquidity for future operations and strategic initiatives. Operationally, the company advanced its key drug candidates, with regulatory updates and clinical trial progress being key themes. The increase in R&D spending is indicative of BeiGene's commitment to its robust pipeline. Investors should note the significant increase in operating expenses, which, while supporting growth, contributed to the widened net loss. The substantial cash reserves provide a buffer against these operating losses and allow for continued investment in development and commercialization efforts.
Aug 6, 2020
2020-Q1
BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2020
BeOne Medicines Ltd. reported a significant increase in cash and cash equivalents to $1.96 billion as of March 31, 2020, driven by substantial financing activities, including a major collaboration with Amgen that provided $2.78 billion in proceeds. Despite this strong liquidity, the company incurred a net loss of $364.9 million for the first quarter of 2020, a notable increase from the prior year's loss of $168.1 million. This widened loss is primarily attributed to a substantial rise in research and development (R&D) expenses, which increased by 70.6% to $304.3 million, and a significant increase in selling, general, and administrative (SG&A) expenses, up 85.8% to $107.1 million. The company's product revenue saw a decline of 9.3% to $52.1 million, impacted by decreased sales of in-licensed products like ABRAXANE and REVLIMID, as well as the suspension of ABRAXANE sales in China due to regulatory issues. However, the initial sales of its internally developed drugs, tislelizumab and BRUKINSA, provided some offset. Investors should note the significant increase in R&D spending, reflecting continued investment in pipeline development, and the ongoing impact of COVID-19 on commercial operations.
May 11, 2020
2019-Q3
BeOne Medicines Ltd. Quarterly Report for Q3 Ended Sep 30, 2019
BeiGene, Ltd.'s (ONC) Q3 2019 report shows a significant increase in product revenue, up 30% year-over-year for the quarter and 78% year-over-year for the nine-month period, driven by sales of ABRAXANE®, REVLIMID®, and VIDAZA® in China. However, this growth was somewhat offset by a complete absence of collaboration revenue compared to the previous year, primarily due to the termination of the Celgene collaboration agreement for tislelizumab. The company continues to invest heavily in research and development, with R&D expenses increasing significantly by 61% for the quarter and 53% for the nine months, reflecting progress in its clinical pipeline, particularly for zanubrutinib and tislelizumab. Consequently, the net loss widened considerably, driven by these R&D investments and increased selling, general, and administrative expenses. Financially, BeiGene ended the period with a robust cash position of approximately $1.3 billion in cash, cash equivalents, and short-term investments, providing ample runway. However, the company's operating activities consumed substantial cash, highlighting the capital-intensive nature of drug development. Investors should note the strategic importance of the announced collaboration with Amgen, which includes a significant equity investment, as well as the continued heavy investment in pipeline development, which is driving losses but also positions the company for potential future growth.
Nov 12, 2019
2019-Q2
BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2019
BeiGene, Ltd.'s Q2 2019 report shows a significant increase in total revenues, driven primarily by a substantial collaboration payment of $150 million related to the termination of its tislelizumab agreement with Celgene. While product revenue from in-licensed drugs in China also saw strong year-over-year growth, the company's significant investments in research and development continue to drive substantial operating losses. R&D expenses increased by 39% for the quarter and 49% year-to-date, reflecting pipeline advancement. The company ended the quarter with a solid cash position, but the ongoing high R&D spend indicates a continued need for capital in the future. Investors should monitor the progress of their key drug candidates and the company's ability to manage its significant R&D investments effectively.
Aug 8, 2019
2019-Q1
BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2019
BeiGene, Ltd. (ONC) reported its first-quarter 2019 financial results, showing significant revenue growth driven by both product sales and collaboration revenue. Total revenues more than doubled year-over-year, reaching $77.8 million. Despite this top-line growth, the company continued to experience substantial operating losses, with a net loss attributable to BeiGene, Ltd. of $167.6 million for the quarter. This widening loss is primarily due to a significant increase in research and development (R&D) expenses, which rose by 63% to $178.4 million, reflecting continued investment in the advancement of its oncology drug pipeline, including zanubrutinib, tislelizumab, and pamiparib. From a balance sheet perspective, the company maintained a strong liquidity position, with cash, cash equivalents, and short-term investments totaling $1.6 billion as of March 31, 2019. This substantial cash balance is crucial for funding ongoing R&D, expanding commercial operations in China, and preparing for potential future product launches. Investors should note the company's substantial R&D spend as it progresses its late-stage clinical candidates, which is a key driver for future potential growth but also contributes to significant ongoing losses.
May 9, 2019
2018-Q3
BeOne Medicines Ltd. Quarterly Report for Q3 Ended Sep 30, 2018
Beigene, Ltd. reported a significant increase in cash and cash equivalents, reaching $643.5 million as of September 30, 2018, up from $239.6 million at the end of 2017. This liquidity boost was largely driven by successful public offerings, including a dual listing on the Hong Kong Stock Exchange. Despite this strong cash position, the company experienced a substantial net loss of $144.0 million for the third quarter and $405.5 million for the first nine months of 2018, primarily due to continued high research and development expenses. Revenue streams shifted significantly, with collaboration revenue decreasing by 93% in Q3 and 78% year-to-date, while product revenue from the distribution of Celgene's oncology drugs in China saw a significant increase of 336% in Q3 and 956% year-to-date. The company continues to invest heavily in its pipeline, with R&D expenses climbing 68% in Q3 and 137% year-to-date, driven by the advancement of key drug candidates like zanubrutinib and tislelizumab. The company also advanced its commercialization efforts in China for in-licensed Celgene products. While the company has a robust cash balance, the substantial ongoing investment in R&D and increasing SG&A expenses, coupled with the lack of internally developed product revenues to date, indicate a continued need for capital to fund operations and development.
Nov 8, 2018
2018-Q2
BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2018
BeiGene, Ltd. (NASDAQ: ONC) reported a widening loss in its Q2 2018 10-Q, with net loss attributable to the company of $156.9 million for the quarter versus $60.5 million a year earlier, and $261.5 million for the six months. Total revenue was $52.8 million, up from nil, driven by $31.4 million of net product sales of ABRAXANE, REVLIMID and VIDAZA in China (distributed under the Celgene license) and $21.4 million of collaboration revenue. Spending is rising fast: R&D expense reached $164.3 million in the quarter (up 248%) and SG&A reached $45.2 million (up 319%), reflecting pivotal trials for zanubrutinib, tislelizumab and pamiparib and a rapidly expanding commercial and global organization. The balance sheet is strong for now. Cash, cash equivalents, restricted cash and short-term investments totaled $1.40 billion at June 30, 2018, after a $757.6 million net follow-on equity raise in January 2018. Operating cash outflow was $221.6 million for the six months, so the company is burning cash quickly. Management states that existing resources should fund operations for at least 12 months, but also says these resources will not be enough to complete all global development or launch all current candidates, implying further financing will be needed. Subsequent to quarter end, BeiGene completed a Hong Kong IPO and global offering on August 8, 2018, raising approximately $870.1 million in net proceeds and becoming dual-listed in the U.S. and Hong Kong. Key pipeline news in the period included preliminary tislelizumab Hodgkin's lymphoma data (overall response rate 72.9%, later updated to 85.7%, with 61.4% complete response) and FDA Fast Track designation for zanubrutinib in Waldenstrom macroglobulinemia, with an NDA planned for the first half of 2019. Investors should weigh the strong pipeline and cash position against an accumulated deficit of $594.9 million and a business that is still years away from meaningful internally developed product revenue.
Aug 9, 2018
2018-Q1
BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2018
BeiGene, Ltd. (ONC) reported a net loss of $105.1 million for the first quarter of 2018, up from $50.6 million a year earlier, as operating spending ramped sharply. Total revenue rose to $32.5 million from nil, driven by $23.3 million of net product sales in China (ABRAXANE, REVLIMID, VIDAZA, licensed from Celgene) and $9.3 million of Celgene collaboration revenue. Research and development expense rose 156% to $109.7 million and SG&A rose 230% to $28.9 million, reflecting pipeline expansion (zanubrutinib, tislelizumab, pamiparib, lifirafenib, BGB-A333) and the build-out of a China commercial organization. Basic and diluted loss per share was $0.16 (ADS: $2.03). Balance sheet strength improved materially. The company raised $757.6 million net in a January 2018 follow-on offering, lifting cash, cash equivalents, restricted cash and short-term investments to roughly $1.48 billion at March 31, 2018, versus about $837 million at year-end 2017. Operating cash burn was $104.5 million in the quarter. Management states existing resources fund operations for at least 12 months, but also says current resources will not be sufficient to complete all global development or launch all current candidates, implying further financing will be needed over time. Key watch items for investors include sustained high R&D and SG&A growth ahead of potential China approvals (management expects to file for zanubrutinib and tislelizumab in China in 2018), the Mirati sitravatinib in-license ($10 million upfront expensed as acquired IPR&D), the Guangzhou biologics facility funded partly through a RMB900 million shareholder loan from GET, the Merck KGaA pamiparib priority-status issue, and evolving China drug-regulation and reimbursement policy. Accumulated deficit reached $438.0 million.
May 9, 2018
2017-Q3
BeOne Medicines Ltd. Quarterly Report for Q3 Ended Sep 30, 2017
BeiGene, Ltd. (ONC) reported a sharply profitable third quarter of 2017, driven almost entirely by a one-time accounting event rather than sustained operating performance. Total revenue for the three months ended September 30, 2017 was $220.2 million, comprising $211.4 million of collaboration (license) revenue recognized from the upfront fee under the Celgene PD-1 (BGB-A317) license, plus $8.8 million of net product revenue from the newly acquired distribution of ABRAXANE, REVLIMID and VIDAZA in China. Net income attributable to BeiGene was $117.4 million for the quarter, versus a loss of $35.5 million a year earlier. For the nine months, net income was only $6.2 million, and the company still reported an accumulated deficit of $231.2 million and negative operating cash flow of $81.0 million. The balance sheet strengthened considerably. Cash, cash equivalents and short-term investments reached $757.4 million at quarter end, up from $368.2 million at year-end 2016, supported by a $188.5 million follow-on equity offering, a $150 million share subscription by Celgene Switzerland, a $132.8 million shareholder loan from GET tied to the Guangzhou biologics facility, and the initial $92.1 million Celgene payment. Importantly, a further $171.0 million of the $263 million Celgene upfront fee is recorded as an unbilled receivable due December 2017, so it is not yet in cash, and the company has recorded $38.6 million as deferred revenue for R&D services that will be recognized over future trial periods. Research and development expense rose 157% to $177.7 million for the nine months, and management expects spending to keep climbing as registrational trials for BGB-3111, BGB-A317, BGB-290 and BGB-283 advance. For investors, the key takeaways are that the quarterly profit is non-recurring, that the company's liquidity runway is improved (management states current resources fund operations for at least 12 months), and that the durability of earnings depends on the commercial ramp of the in-licensed Celgene China portfolio, future milestones, and the company's ability to convert its pipeline into approvals. Risk disclosures highlight dependence on China regulatory policy, pending PRC pricing reforms, a Nasdaq audit-committee compliance gap, and the loss of emerging growth company status at year-end 2017.
Nov 13, 2017
2017-Q2
BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2017
BeiGene, Ltd.'s Form 10-Q for the quarter ended June 30, 2017 shows a clinical-stage oncology company that is still pre-revenue and spending heavily to advance its pipeline. Note that the filing is BeiGene, Ltd.'s (NASDAQ: BGNE) report; the ticker and company name in the request do not match the document. For Q2 2017, the company reported no revenue, operating expenses of $58.0 million (R&D of $47.2 million, up 124% year over year, and G&A of $10.8 million), and a net loss of $60.7 million. For the first six months, the net loss was $111.3 million, and cash used in operations was $87.6 million. The accumulated deficit reached $348.6 million. Liquidity improved on paper during the period. Cash, cash equivalents and short-term investments totaled $407.4 million at June 30, 2017, up from $368.2 million at year-end 2016. That increase was driven mainly by a RMB900 million (about $135 million) shareholder loan from Guangzhou GET Technology, carrying 8% interest over 72 months, and a $14.5 million capital contribution from GET to BeiGene Biologics, the company's 95%-owned Chinese biologics subsidiary. About $155.2 million of the cash balance is held by that subsidiary and restricted to its facility build-out and China biologics R&D. Management states the company has sufficient cash for at least 12 months, but the risk factors say existing cash will not be sufficient to complete all global development or launch current candidates, so further financing is expected. The filing's largest forward-looking event is the July 5, 2017 Celgene transaction, expected to close in Q3 2017. It includes $263 million in upfront license fees, a $150 million equity purchase at $4.58 per share (about 32.7 million shares, roughly 5.9% dilution), up to $980 million in milestones and royalties on BGB-A317, and the acquisition of Celgene's China commercial operations. The filing has not closed yet, so these figures are pending and subject to closing conditions.
Aug 9, 2017
2017-Q1
BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2017
BeiGene, Ltd. (ONC) reported its first quarter 2017 financial results, showcasing a significant increase in research and development (R&D) expenses as the company continued to advance its clinical-stage oncology pipeline. Total operating expenses more than doubled year-over-year, driven primarily by R&D investments in key drug candidates like BGB-3111, BGB-A317, BGB-290, and BGB-283. The company reported a net loss of $50.6 million, widening from $22.0 million in the prior year’s quarter, reflecting its ongoing commitment to drug development. Financially, BeiGene ended the quarter with $327.5 million in cash, cash equivalents, and short-term investments, indicating a solid liquidity position to fund operations for at least the next twelve months, following successful IPO and follow-on offerings in 2016. Revenue from collaboration agreements was nil, down from $0.7 million in Q1 2016, as earlier collaborations with Merck KGaA concluded. The company continues to focus on building its manufacturing capabilities and expanding its global operations, with significant capital expenditures noted for its Suzhou and Guangzhou facilities.
May 10, 2017
2016-Q3
BeOne Medicines Ltd. Quarterly Report for Q3 Ended Sep 30, 2016
BeiGene, Ltd. (ONC) reported its Q3 2016 results in a 10-Q filed November 10, 2016, the first full quarter after its February 8, 2016 IPO on NASDAQ, which raised net proceeds of $166.2 million. The company remains a clinical-stage oncology company with no approved products and no product revenue. Collaboration revenue fell to nil for the third quarter (nine-month revenue of $1.1 million, down from $4.1 million) as recognition of BGB-290 revenue ceased after the October 2015 repurchase of its ex-PRC rights from Merck KGaA. Net loss widened to $35.5 million for the quarter and $81.6 million for the nine months, versus $14.0 million and $29.9 million a year earlier, driven by R&D expense rising to $30.1 million in the quarter ($69.1 million year-to-date) as clinical programs BGB-3111, BGB-A317, BGB-290 and BGB-283 advanced. Liquidity improved substantially: cash, cash equivalents and short-term investments totaled $203.6 million at September 30, 2016, up from $100.5 million at year-end 2015, and shareholders' equity swung to $187.8 million from a deficit of $(101.8) million following the conversion of preferred shares and the senior note at IPO. Operating cash burn was $63.4 million for the nine months. Management states current resources fund operations for at least 12 months, but the risk factors explicitly say IPO proceeds plus existing cash are insufficient to complete global development or commercial launch of current candidates, so additional financing is expected. Investors should also note disclosed risks: a material weakness in internal control over financial reporting (insufficient GAAP/SEC reporting personnel) remains under remediation; roughly 72.9% of ordinary shares are held by directors, officers and principal shareholders; there is significant PRC regulatory, tax and currency exposure given that most operations are in China; and an outside auditor not fully inspected by the PCAOB. The company also disclosed Brexit-related and patent-related risks, including third-party patents relevant to BGB-A317 and BGB-3111.
Nov 10, 2016
2016-Q2
BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2016
BeiGene, Ltd. (ONC) reported its first quarter-end results as a newly public company in this 10-Q for the period ended June 30, 2016, filed August 10, 2016, following its February 8, 2016 NASDAQ IPO that raised net proceeds of $166.2 million. The company is a clinical-stage oncology biopharmaceutical developer with no approved products and no product revenue. Collaboration revenue from the Merck KGaA arrangements fell to $0.4 million in Q2 2016 (from $1.4 million a year earlier) and $1.1 million for the six months, as revenue tied to BGB-290 stopped after the company repurchased those ex-China rights in October 2015. Operating losses widened sharply as the company expanded its clinical pipeline. R&D expense rose to $21.1 million in the quarter (from $6.7 million) and $39.0 million for the half-year, driven mainly by external clinical trial costs for BGB-3111, BGB-A317, BGB-290 and BGB-283. Net loss was $24.1 million for Q2 2016 and $46.1 million for the six months, versus $5.6 million and $15.9 million a year earlier. Accumulated deficit reached $164.3 million. Operating cash burn was $39.1 million for the six months, and cash, cash equivalents and short-term investments totaled $226.6 million at June 30, 2016, up from $100.5 million at year-end 2015. Management states this is sufficient for at least the next 12 months, though the filing also says IPO proceeds alone will not fund full global development or launch, implying future financing will be needed. Investors should also note the disclosed material weakness in internal control over financial reporting, tied to insufficient accounting personnel, which management is remediating. The company is a Cayman Islands entity with substantially all operations in China, and it flags PRC regulatory, currency, tax and PCAOB inspection risks. Founders and principal shareholders control about 66.4% of ordinary shares, and the company is an emerging growth company.
Aug 10, 2016
2016-Q1
BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2016
BeiGene, Ltd. (NASDAQ: ONC) reported its first quarter 2016 results as a newly public company, following its February 8, 2016 IPO that raised net proceeds of $166.2 million at $24.00 per ADS. The company is a clinical-stage biopharmaceutical developer focused on molecularly targeted and immuno-oncology cancer drugs, with no approved products and no product revenue to date. For the three months ended March 31, 2016, net loss widened to $22.0 million from $10.2 million a year earlier, driven by R&D expense rising 78% to $17.9 million as the pipeline (BGB-3111, BGB-A317, BGB-290, BGB-283) advanced, and G&A rising to $3.1 million from $1.1 million as the company built public-company infrastructure. Collaboration revenue fell to $0.7 million from $1.4 million because BGB-290 revenue ceased after the ex-PRC rights were repurchased from Merck KGaA in October 2015. The balance sheet was transformed by the IPO. Cash, cash equivalents and short-term investments totaled $247.2 million at March 31, 2016, versus $100.5 million at year-end 2015, and shareholders' equity moved from a deficit of $101.8 million to positive equity of $243.1 million after conversion of all preferred shares and the Senior Promissory Note into ordinary shares. Operating cash burn was $19.8 million in the quarter. Management states the current resources should fund operations for at least 12 months, but also acknowledges that the IPO proceeds alone will not be sufficient to complete all planned global development or commercial launches, implying future financing needs. Investors should weigh the significant clinical-stage risk profile, the company's reliance on its four lead candidates, a disclosed material weakness in internal control over financial reporting, a Cayman Islands structure with substantial PRC operations and related regulatory and audit-inspection risks, and a concentrated shareholder base (about 65.5% held by directors, officers and principal shareholders). A large share of outstanding shares (about 74.4%) remains subject to lock-up restrictions that are scheduled to begin expiring as early as August 1, 2016.
May 12, 2016